TransCode Therapeutics (NASDAQ:RNAZ) Posts Quarterly Earnings Results

TransCode Therapeutics (NASDAQ:RNAZ) released its quarterly earnings data on Friday. The company reported ($21.28) EPS for the quarter, FiscalAI reports.

TransCode Therapeutics Stock Performance

NASDAQ RNAZ traded down $0.19 during mid-day trading on Friday, reaching $6.60. 6,370 shares of the stock were exchanged, compared to its average volume of 6,821. The business’s 50 day moving average is $8.58 and its 200-day moving average is $8.96. TransCode Therapeutics has a 1 year low of $6.08 and a 1 year high of $20.99. The company has a market capitalization of $6.07 million, a P/E ratio of -0.07 and a beta of 1.39.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.